Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study

Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b...

Full description

Saved in:
Bibliographic Details
Published in:PLoS ONE 2022, Vol.17 (5), p.e0268529
Main Authors: Iwamoto, Momoko, Ukimura, Akira, Ogawa, Taku, Kawanishi, Fumiko, Osaka, Naofumi, Kubota, Mari, Mori, Tatsuhiko, Sawamura, Ritsuko, Nishihara, Masami, Suzuki, Tomio, Uchiyama, Kazuhisa
Format: Report
Language:English
Subjects:
Analysis
Antibodies
Complications and side effects
Health aspects
Hepatitis B virus
Immune response
Messenger RNA
Patient outcomes
Prevention
Vaccination
Viral antibodies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page e0268529
container_title PLoS ONE
container_volume 17
creator Iwamoto, Momoko
Ukimura, Akira
Ogawa, Taku
Kawanishi, Fumiko
Osaka, Naofumi
Kubota, Mari
Mori, Tatsuhiko
Sawamura, Ritsuko
Nishihara, Masami
Suzuki, Tomio
Uchiyama, Kazuhisa
description Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine. We prospectively tested 954 healthcare workers for the Anti-SARS-CoV-2 spike (S) protein antibody titers prior to the first and second BNT162b2 vaccination doses and after four weeks after the second dose using Roche's Elecsys.sup.® assay. We calculated the percentage of patients who seroconverted after the first and second doses. We estimated the relative risk of non-seroconversion after the first BNT162b2 vaccine (defined as anti-SARS-CoV-2-S titer
doi_str_mv 10.1371/journal.pone.0268529
format report
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_ISR_A703978299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A703978299</galeid><sourcerecordid>A703978299</sourcerecordid><originalsourceid>FETCH-gale_incontextgauss_ISR_A7039782993</originalsourceid><addsrcrecordid>eNqVT01PwkAU3BhNxI9_4OHdjIdCuw2FeitEgx6IAcKVbJcHXSj7mn3LR_2x_hYJ0cjVw2Qmk8lMRoiHKGxGcSdqrWjrrCqbFVlshjLptmV6IRpRGssgkWF8eaavxQ3zKgzbcTdJGuIrYyZtlDdkIUe_R7RQGPbkaqAFDHpT2CmtjUVwyMcFRlB2foQ3wTgbjYM-TQMJXJk1ntyc5vVf1hP4AqFnaDhBXbQ-FuYT3SNDbziJEplL2IyGGZw1_c6pDdklFKhKX2jlEPbk1ugYjIV3VSn7DBlUjrhC7c0OgXJGtztdUSWw387rO3G1UCXj_Q_fiqfXl0l_ECxViTNjNVmPB79UW-bZ23g0yzphnHa6Mk3j_2S_AXz0ffg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Iwamoto, Momoko ; Ukimura, Akira ; Ogawa, Taku ; Kawanishi, Fumiko ; Osaka, Naofumi ; Kubota, Mari ; Mori, Tatsuhiko ; Sawamura, Ritsuko ; Nishihara, Masami ; Suzuki, Tomio ; Uchiyama, Kazuhisa</creator><creatorcontrib>Iwamoto, Momoko ; Ukimura, Akira ; Ogawa, Taku ; Kawanishi, Fumiko ; Osaka, Naofumi ; Kubota, Mari ; Mori, Tatsuhiko ; Sawamura, Ritsuko ; Nishihara, Masami ; Suzuki, Tomio ; Uchiyama, Kazuhisa</creatorcontrib><description>Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine. We prospectively tested 954 healthcare workers for the Anti-SARS-CoV-2 spike (S) protein antibody titers prior to the first and second BNT162b2 vaccination doses and after four weeks after the second dose using Roche's Elecsys.sup.® assay. We calculated the percentage of patients who seroconverted after the first and second doses. We estimated the relative risk of non-seroconversion after the first BNT162b2 vaccine (defined as anti-SARS-CoV-2-S titer &lt;15 U/mL) among HBV vaccine non-responders (HBs-Ab titer &lt;10 mIU/mL) and weak responders ([greater than or equal to]10 and &lt;100 mIU/mL) compared to normal responders ([greater than or equal to]100 mIU/mL). Among 954 healthcare workers recruited between March 9 and March 24, 2021 at Osaka Medical and Pharmaceutical University, weak and normal HBV vaccine responders had comparable S-protein titers after the first BNT162b2 dose (51.4 [95% confidence interval 25.2-137.0] versus 59.7 [29.8-138.0] U/mL, respectively). HBV vaccine non-responders were more likely than normal responders to not seroconvert after a single dose (age and sex-adjusted relative risk 1.85 95% confidence interval [1.10-3.13]) although nearly all participants seroconverted after the second dose. After limiting the analysis to 382 patients with baseline comorbidity data, the comorbidity-adjusted relative risk of non-seroconversion among HBV vaccine non-responders to normal responders was 1.32 (95% confidence interval [0.59-2.98]). Long term follow-up studies are needed to understand if protective immunity against SARS-CoV-2 wanes faster among those with history of HBV vaccine non-response and when booster doses are warranted for these healthcare workers.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0268529</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Analysis ; Antibodies ; Complications and side effects ; Health aspects ; Hepatitis B virus ; Immune response ; Messenger RNA ; Patient outcomes ; Prevention ; Vaccination ; Viral antibodies</subject><ispartof>PLoS ONE, 2022, Vol.17 (5), p.e0268529</ispartof><tpages>e0268529</tpages><format>e0268529</format><rights>COPYRIGHT 2022 Public Library of Science</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,4476,27902</link.rule.ids></links><search><creatorcontrib>Iwamoto, Momoko</creatorcontrib><creatorcontrib>Ukimura, Akira</creatorcontrib><creatorcontrib>Ogawa, Taku</creatorcontrib><creatorcontrib>Kawanishi, Fumiko</creatorcontrib><creatorcontrib>Osaka, Naofumi</creatorcontrib><creatorcontrib>Kubota, Mari</creatorcontrib><creatorcontrib>Mori, Tatsuhiko</creatorcontrib><creatorcontrib>Sawamura, Ritsuko</creatorcontrib><creatorcontrib>Nishihara, Masami</creatorcontrib><creatorcontrib>Suzuki, Tomio</creatorcontrib><creatorcontrib>Uchiyama, Kazuhisa</creatorcontrib><title>Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study</title><title>PLoS ONE</title><description>Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine. We prospectively tested 954 healthcare workers for the Anti-SARS-CoV-2 spike (S) protein antibody titers prior to the first and second BNT162b2 vaccination doses and after four weeks after the second dose using Roche's Elecsys.sup.® assay. We calculated the percentage of patients who seroconverted after the first and second doses. We estimated the relative risk of non-seroconversion after the first BNT162b2 vaccine (defined as anti-SARS-CoV-2-S titer &lt;15 U/mL) among HBV vaccine non-responders (HBs-Ab titer &lt;10 mIU/mL) and weak responders ([greater than or equal to]10 and &lt;100 mIU/mL) compared to normal responders ([greater than or equal to]100 mIU/mL). Among 954 healthcare workers recruited between March 9 and March 24, 2021 at Osaka Medical and Pharmaceutical University, weak and normal HBV vaccine responders had comparable S-protein titers after the first BNT162b2 dose (51.4 [95% confidence interval 25.2-137.0] versus 59.7 [29.8-138.0] U/mL, respectively). HBV vaccine non-responders were more likely than normal responders to not seroconvert after a single dose (age and sex-adjusted relative risk 1.85 95% confidence interval [1.10-3.13]) although nearly all participants seroconverted after the second dose. After limiting the analysis to 382 patients with baseline comorbidity data, the comorbidity-adjusted relative risk of non-seroconversion among HBV vaccine non-responders to normal responders was 1.32 (95% confidence interval [0.59-2.98]). Long term follow-up studies are needed to understand if protective immunity against SARS-CoV-2 wanes faster among those with history of HBV vaccine non-response and when booster doses are warranted for these healthcare workers.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Complications and side effects</subject><subject>Health aspects</subject><subject>Hepatitis B virus</subject><subject>Immune response</subject><subject>Messenger RNA</subject><subject>Patient outcomes</subject><subject>Prevention</subject><subject>Vaccination</subject><subject>Viral antibodies</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2022</creationdate><recordtype>report</recordtype><recordid>eNqVT01PwkAU3BhNxI9_4OHdjIdCuw2FeitEgx6IAcKVbJcHXSj7mn3LR_2x_hYJ0cjVw2Qmk8lMRoiHKGxGcSdqrWjrrCqbFVlshjLptmV6IRpRGssgkWF8eaavxQ3zKgzbcTdJGuIrYyZtlDdkIUe_R7RQGPbkaqAFDHpT2CmtjUVwyMcFRlB2foQ3wTgbjYM-TQMJXJk1ntyc5vVf1hP4AqFnaDhBXbQ-FuYT3SNDbziJEplL2IyGGZw1_c6pDdklFKhKX2jlEPbk1ugYjIV3VSn7DBlUjrhC7c0OgXJGtztdUSWw387rO3G1UCXj_Q_fiqfXl0l_ECxViTNjNVmPB79UW-bZ23g0yzphnHa6Mk3j_2S_AXz0ffg</recordid><startdate>20220516</startdate><enddate>20220516</enddate><creator>Iwamoto, Momoko</creator><creator>Ukimura, Akira</creator><creator>Ogawa, Taku</creator><creator>Kawanishi, Fumiko</creator><creator>Osaka, Naofumi</creator><creator>Kubota, Mari</creator><creator>Mori, Tatsuhiko</creator><creator>Sawamura, Ritsuko</creator><creator>Nishihara, Masami</creator><creator>Suzuki, Tomio</creator><creator>Uchiyama, Kazuhisa</creator><general>Public Library of Science</general><scope>ISR</scope></search><sort><creationdate>20220516</creationdate><title>Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study</title><author>Iwamoto, Momoko ; Ukimura, Akira ; Ogawa, Taku ; Kawanishi, Fumiko ; Osaka, Naofumi ; Kubota, Mari ; Mori, Tatsuhiko ; Sawamura, Ritsuko ; Nishihara, Masami ; Suzuki, Tomio ; Uchiyama, Kazuhisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_incontextgauss_ISR_A7039782993</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Complications and side effects</topic><topic>Health aspects</topic><topic>Hepatitis B virus</topic><topic>Immune response</topic><topic>Messenger RNA</topic><topic>Patient outcomes</topic><topic>Prevention</topic><topic>Vaccination</topic><topic>Viral antibodies</topic><toplevel>online_resources</toplevel><creatorcontrib>Iwamoto, Momoko</creatorcontrib><creatorcontrib>Ukimura, Akira</creatorcontrib><creatorcontrib>Ogawa, Taku</creatorcontrib><creatorcontrib>Kawanishi, Fumiko</creatorcontrib><creatorcontrib>Osaka, Naofumi</creatorcontrib><creatorcontrib>Kubota, Mari</creatorcontrib><creatorcontrib>Mori, Tatsuhiko</creatorcontrib><creatorcontrib>Sawamura, Ritsuko</creatorcontrib><creatorcontrib>Nishihara, Masami</creatorcontrib><creatorcontrib>Suzuki, Tomio</creatorcontrib><creatorcontrib>Uchiyama, Kazuhisa</creatorcontrib><collection>Science In Context</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwamoto, Momoko</au><au>Ukimura, Akira</au><au>Ogawa, Taku</au><au>Kawanishi, Fumiko</au><au>Osaka, Naofumi</au><au>Kubota, Mari</au><au>Mori, Tatsuhiko</au><au>Sawamura, Ritsuko</au><au>Nishihara, Masami</au><au>Suzuki, Tomio</au><au>Uchiyama, Kazuhisa</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study</atitle><jtitle>PLoS ONE</jtitle><date>2022-05-16</date><risdate>2022</risdate><volume>17</volume><issue>5</issue><spage>e0268529</spage><pages>e0268529-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine. We prospectively tested 954 healthcare workers for the Anti-SARS-CoV-2 spike (S) protein antibody titers prior to the first and second BNT162b2 vaccination doses and after four weeks after the second dose using Roche's Elecsys.sup.® assay. We calculated the percentage of patients who seroconverted after the first and second doses. We estimated the relative risk of non-seroconversion after the first BNT162b2 vaccine (defined as anti-SARS-CoV-2-S titer &lt;15 U/mL) among HBV vaccine non-responders (HBs-Ab titer &lt;10 mIU/mL) and weak responders ([greater than or equal to]10 and &lt;100 mIU/mL) compared to normal responders ([greater than or equal to]100 mIU/mL). Among 954 healthcare workers recruited between March 9 and March 24, 2021 at Osaka Medical and Pharmaceutical University, weak and normal HBV vaccine responders had comparable S-protein titers after the first BNT162b2 dose (51.4 [95% confidence interval 25.2-137.0] versus 59.7 [29.8-138.0] U/mL, respectively). HBV vaccine non-responders were more likely than normal responders to not seroconvert after a single dose (age and sex-adjusted relative risk 1.85 95% confidence interval [1.10-3.13]) although nearly all participants seroconverted after the second dose. After limiting the analysis to 382 patients with baseline comorbidity data, the comorbidity-adjusted relative risk of non-seroconversion among HBV vaccine non-responders to normal responders was 1.32 (95% confidence interval [0.59-2.98]). Long term follow-up studies are needed to understand if protective immunity against SARS-CoV-2 wanes faster among those with history of HBV vaccine non-response and when booster doses are warranted for these healthcare workers.</abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0268529</doi><tpages>e0268529</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PLoS ONE, 2022, Vol.17 (5), p.e0268529
issn 1932-6203
1932-6203
language eng
recordid cdi_gale_incontextgauss_ISR_A703978299
source Open Access: PubMed Central; Publicly Available Content (ProQuest)
subjects Analysis
Antibodies
Complications and side effects
Health aspects
Hepatitis B virus
Immune response
Messenger RNA
Patient outcomes
Prevention
Vaccination
Viral antibodies
title Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T23%3A40%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Association%20between%20history%20of%20HBV%20vaccine%20response%20and%20anti-SARS-CoV-2%20spike%20antibody%20response%20to%20the%20BioNTech/Pfizer's%20BNT162b2%20mRNA%20SARS-CoV-2%20vaccine%20among%20healthcare%20workers%20in%20Japan:%20A%20prospective%20observational%20study&rft.jtitle=PLoS%20ONE&rft.au=Iwamoto,%20Momoko&rft.date=2022-05-16&rft.volume=17&rft.issue=5&rft.spage=e0268529&rft.pages=e0268529-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0268529&rft_dat=%3Cgale%3EA703978299%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-gale_incontextgauss_ISR_A7039782993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A703978299&rfr_iscdi=true